NASDAQ : VRDN
Viridian Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 24.8 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.81B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.87B |
| Enterprise Value | 2.13B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 113.29M |
| Shares Outstanding | 113.29M |
| Shares Change (YoY) | +24.83% |
| Shares Change (QoQ) | +5.55% |
| Owned by Insiders (%) | 0.08% |
| Owned by Institutions (%) | 108.85% |
| Float | 100.79M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 40.30 |
| Forward PS | 21.43 |
| PB Ratio | 5.08 |
| P/TBV Ratio | 5.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 29.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 16.95 |
| Quick Ratio | 16.56 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -25.95 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -65.74% |
| Return on Assets (ROA) | -30.16% |
| Return on Invested Capital (ROIC) | -35.05% |
| Return on Capital Employed (ROCE) | -39.21% |
| Weighted Average Cost of Capital (WACC) | 9.76% |
| Revenue Per Employee | $282,250 |
| Profits Per Employee | -$1.33M |
| Employee Count | 252 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.07 |
| 52-Week Price Change | +7.07% |
| 50-Day Moving Average | 21.68 |
| 200-Day Moving Average | 21.72 |
| Relative Strength Index (RSI) | 72.25 |
| Average Volume (20 Days) | 2,101,929 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 18.00M |
| Short Previous Month | 17.97M |
| Short % of Shares Out | 15.89% |
| Short % of Float | 17.86% |
| Short Ratio (days to cover) | 8.44 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 71.13M |
| Gross Profit | -253.55M |
| Operating Income | -405.20M |
| Pretax Income | -386.97M |
| Net Income | -334.03M |
| EBITDA | -404.73M |
| EBIT | -405.20M |
| Loss Per Share | -$3.46 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 981.53M |
| Total Debt | 244.73M |
| Net Cash | 736.80M |
| Net Cash Per Share | $6.50 |
| Equity (Book Value) | 662.10M |
| Book Value Per Share | 4.98 |
| Working Capital | 1.02B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -333.34M |
| Capital Expenditures | -1.70M |
| Depreciation & Amortization | 468,000 |
| Net Borrowing | 224.18M |
| Free Cash Flow | -335.04M |
| FCF Per Share | -$2.96 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -569.68% |
| Pretax Margin | -544.06% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -24.83% |
| Shareholder Yield | -24.83% |
| Earnings Yield | -13.67% |
| FCF Yield | -11.69% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $36.20 |
| Price Target Difference | 43.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | 103.50% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 13, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.93 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |